Form 4: CEO Clay Shorrock Acquires 18,691 Shares in Applied DNA Sciences

Applied DNA Sciences CEO Clay Shorrock acquired 18,691 shares of common stock through a restricted stock unit grant, vesting in 90 days.

Summary

• Clay Shorrock, Chief Executive Officer of Applied DNA Sciences Inc. (BNBX), acquired 18,691 shares of common stock on October 17, 2025.
• The acquisition was in the form of a restricted stock unit (RSU) grant, with a transaction price of $0 per share.
• These restricted stock units are scheduled to vest 100% upon 90 days from the grant date.
• Following this transaction, Mr. Shorrock directly beneficially owns a total of 18,695 shares of common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by the CEO is generally a positive signal, indicating increased alignment of management's interests with shareholders. While not a cash purchase, it ties the CEO's future wealth directly to the company's stock performance.

Positives

• Increased alignment of CEO Clay Shorrock's interests with those of shareholders through the acquisition of 18,691 restricted stock units.
• The grant of restricted stock units at a $0 price indicates a performance or retention incentive, aligning management compensation with company performance.
• The transaction was executed under a Rule 10b5-1 plan, demonstrating a pre-planned and transparent approach to insider trading.

Negatives

• The acquisition was a grant of restricted stock units, not an open market purchase, meaning no direct cash investment by the CEO.
• The shares are restricted and will only fully vest after 90 days from the grant date, meaning immediate liquidity is not available.

Risks

• The value of the restricted stock units is subject to the future market price of Applied DNA Sciences Inc. common stock.
• Failure to meet potential performance conditions (if any, though not specified here beyond time-based vesting) could impact the ultimate value or receipt of the shares.

Future Outlook

The 18,691 restricted stock units granted to CEO Clay Shorrock are scheduled to vest 100% upon 90 days from the grant date of October 17, 2025.

Industry Context

Insider grants of restricted stock units are a common form of executive compensation, designed to align management incentives with long-term shareholder value creation. The use of a Rule 10b5-1 plan is standard practice for executives to manage their stock transactions in compliance with insider trading regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to greater alignment of CEO's financial interests with company performance.
• Employees: May signal stability and management's long-term commitment to the company.

Next Steps

• The restricted stock units will vest 100% approximately 90 days from the grant date of October 17, 2025.

Key Dates

Recommendation

The acquisition of restricted stock units by CEO Clay Shorrock is a positive indicator of management's commitment and alignment with shareholder interests. While not a direct cash investment, it increases insider ownership and ties executive compensation to the company's stock performance. This generally reinforces a 'hold' recommendation, suggesting continued monitoring of the company's fundamentals and strategic execution.

Keywords

Applied DNA Sciences, BNBX, Clay Shorrock, CEO, insider transaction, Form 4, restricted stock units, RSU, stock grant, beneficial ownership, corporate governance, Rule 10b5-1